HL-161B

HL-161B is a topical small molecule MEK inhibitor being developed by KeChow Pharma for the treatment of solid tumors. It specifically targets the MAPK/ERK signaling pathway by inhibiting mitogen-activated protein kinase kinase (MEK), a critical node that is frequently hyperactivated in various malignancies. By utilizing a topical route of administration, HL-161B is designed to deliver therapeutic concentrations of the drug directly to accessible tumor sites or cutaneous manifestations of cancer, potentially minimizing the systemic toxicities often associated with oral MEK inhibitors. It is part of a series of topical formulations, including HL-161A, currently in early-stage development.